PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications.
Molecular Weight:
373.41
Purity:
98.85%
CAS Number:
[368434-98-4]
Formula:
C18H23N5O4
Target:
Others|||Serine/threonin kinase|||LDLR
T72025
* VAT and and shipping costs not included. Errors and price changes excepted